Live Up to Blossom Years and Strive Forward -- MEDICA - World Forum for Medicine

09.04.2020

Hzymes Biotechnology Co., Ltd.

Live Up to Blossom Years and Strive Forward

   During the spring festival of 2020, the Coronavirus epidemic has quickly spreading all over the world. To facing the sudden change, Shanghai Hanover Biotechnology Co., LTD. (hereinafter referred to as Hanover) Hanhai New Enzyme R&D and marketing center of Shanghai, took fully respond to promote the operation preparation of R & D and management center in Fengchuang Valley.   
   As a global supplier of IVD (In Vitro Diagnostic) raw material, Hanhai New Enzyme Biotechnology is devoted to providing high quality product and efficient solutions for global manufacturer of In Vitro Diagnostic Reagents. In medical field, 70% of diagnosis and treatment decisions are make with the help of In Vitro Diagnostic Products. According to the estimation by Evaluate MedTdch, the global in vitro diagnostic market scale reached to $70 billion, core material market size achieved over $10.5 billion. In 2019, China’s in vitro diagnostic market size is around $80 billion, vital raw material market scale is at $12 billion. Most of the companies can provide these core raw materials (key enzyme antigen antibody color substrate, etc.) are foreign enterprises.

Relying on our own research and development team, we have developed more than 60 kinds of core enzymes for in vitro diagnostic reagents using the enzyme function evolution and high-throughput screening technology platform, covering more than 80% of the product lines in the biochemical field. At the same time, the application environment of various core enzymes and the best formula to explore, to provide customers with the overall solution from raw materials to the process. Among them, HbA1c test reagent has been approved by European customers. At the same time, the marketing team has been constantly exploring customer needs and developing chemiluminescence substrates (APS-5) to replace imported products, which have been recognized by domestic listed in vitro diagnostic enterprises. The officially operation of Shanghai Hanover Biotechnology research & management center will speed up the company in various fields of in vitro diagnostic core raw material layout, also provide support for the comprehensive development of overseas market while facing the impact of the epidemic, but we believe that our these with independent research and development ability of enterprises in China can translate crisis into opportunity, seize the great opportunity for the development of health industry 

Exhibitor Data Sheet